An update on the clinical development of drugs to disable tumor vasculature

Expert Opinion on Drug Discovery

Volumn 2, Issue 10, 2007, Pages 1357-1367

  Siemann, Dietmar W ^a   Chaplin, David J ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b OXiGENE Inc   (United States)

Author keywords

Blood vessel; Tumor; Vascular disrupting agent; Vasculature targeting

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ASA 404; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; COMBRETASTATIN A1 PHOSPHATE; CYT 997; DOCETAXEL; ENDOSTATIN; EXHERIN; FUMAGILLOL CHLOROACETYLCARBAMATE; MITOFLAXONE; MN 029; MPC 6827; N ACETYLCOLCHINOL PHOSPHATE; NPI 2358; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SU 5474; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; VASCULOTROPIN; VATALANIB; ZYBRESTAT;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ALOPECIA; ANXIETY; BLOOD FLOWMETRY; BONE MARROW DISEASE; BRAIN INFARCTION; BRAIN ISCHEMIA; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CELL KILLING; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONFUSION; CONSTIPATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG RESEARCH; DRUG TARGETING; DYSGEUSIA; DYSPNEA; ELECTROCARDIOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; HEADACHE; HEART EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HEMATOLOGIC DISEASE; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL SUPPORT; OVARY CANCER; PAIN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SLURRED SPEECH; STOMATITIS; THROMBOCYTOPENIA; THYROID CANCER; TREMOR; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; VISUAL DISORDER; VOMITING;

EID: 35348905631     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.10.1357     Document Type: Review

References (76)

1. FOLKMAN J: Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. (2002) 29:15-18.
2. HENDRIX MJ, SEFTOR EA, HESS AR, SEFTOR RE: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer (2003) 3:411-421.
3. STREUBEL B, CHOTT A, HUBER D et al.: Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N. Engl. J. Med. (2004) 351:250-259.
4. KONERDING MA, VAN ACKERN C, FAIT E, STEINBERG F, STREFFER C: Morphological aspects of tumor angiogenesis and microcirculation. In: Blood Perfusion and Microenvironment of Human Tumors. Molls M, Vaupel P (Eds), Springer, Berlin, Germany (2002):5-17.
5. OVERGAARD J, HORSMAN MR: Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin. Radiat. Oncol. (1996) 6:10-21.
6. YOUNG SD, MARSHALL RS, HILL RP: Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc. Natl. Acad. Sci. USA (1988) 85:9533-9537.
7. GIACCIA AJ, BROWN JM, WOUTERS B, DENKO N, KOUMENIS C: Cancer therapy and tumor physiology. Science (1998) 279:12-13.
8. SIEMANN DW, BIBBY MC, DARK GG et al.: Differentiation and definition of vascular-targeted therapies. Clin. Cancer Res. (2005) 11:416-420.
9. HARRIS AL: Antiangiogenesis for cancer therapy. Lancet (1997) 349(Suppl. 2):SII13-SII15.
10. KERBEL RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis (2000) 21:505-515.
11. HURWITZ HI, FEHRENBACHER L, HAINSWORTH JD et al.: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. (2005) 23:3502-3508.
12. DENEKAMP J: The tumour microcirculation as a target in cancer therapy: a clearer perspective. Eur. J. Clin. Invest. (1999) 29:733-736.
13. SIEMANN DW, CHAPLIN DJ, HORSMAN MR: Vascular-targeting therapies for treatment of malignant disease. Cancer (2004) 100:2491-2499.
14. CHAPLIN DJ, PETTIT GR, HILL SA: Anti-vascular approaches to solid tumout therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. (1999) 19:189-195.
15. THORPE PE: Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. (2004) 10:415-427.
16. CHAPLIN DJ, HORSMAN MR, SIEMANN DW: Small molecule vascular disrupting agents (VDAs): current status. Curr. Opin. Investig. Drugs (2006) 7:522-528.
17. TOZER GM, KANTHOU C, BAGULEY BC: Disrupting tumour blood vessels. Nat. Revs. Cancer (2005) 5:423-435.
18. BAGULEY BC: Antivascular therapy of cancer: DMXAA. Lancet Oncol. (2003) 4:141-148.
19. VINCENT L, KERMANI P, YOUNG L M et al.: Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothehal-cadherin signaling. J. Clin. Invest. (2005) 115:2992-3006.
20. HOBSON B, DENEKAMP J: Endothelial proliferation in rumors and normal tissue: continuous labeling studies. Br. J. Cancer (1984) 49:405-413.
21. EBERHARD A, KAHLERT S, GOEDEV, HEMMERLEIN B, PLATE KH, AUGUSTINE HG: Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. (2000) 60:1388-1393.
22. SIEMANN DW SHI W. Efficacy of combined antiangiogenic and vascular disrupting agents in the treatment of solid tumors. Int. J. Radiat. Oncol. Biol. Phys. (2004) 60:1233-1240.
23. HORSMAN MR, SIEMANN DW: Pathophysiological effects of vascular targeting agents and the implications for combination with conventional therapies. Cancer Res. (2006) 66:11520-11539.
24. SIEMANN DW, RQJIANI AM: The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int. J. Radiat. Oncol. Biol. Phys. (2005) 62:846-853.
25. LANDUYT W, AHMED B, NUYTS S et al.: In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int. J. Radiat. Oncol. Biol. Phys. (2001) 49:443-450.
26. LASH CJ, LI AE, RUTLAND M, BAGULEY BC, ZWI LJ, WILSON WR-. Enhancement of the anti-tumour eflects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br. J. Cancer (1998) 78:439-445.
27. GROSIOS K, LOADMAN PM, SWAINE DJ, PETTIT GR, BIBBY MC: Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res. (2000) 20:229-233.
28. SIEMANN DW, MERCER E, LEFLER SE, ROJIANI AM: Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int. J. Cancer (2002) 99:1-6.
29. SIEMANN DW, R0JIANI AM: Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys. (2002) 53:164-171.
30. WILSON WR, LI AE, COWAN DS, SLIM BG: Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxandienone-4-acetic acid. Int. J. Radiat. Oncol. Biol. Phys. (1998) 42:905-908.
31. MURATA R, SIEMANN DW, OVERGAARD J, HORSMAN MR. Improved tumor response by combining radiation and the vascular damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat. Res. (2001) 156:503-509.
32. HORSMAN MR, MURATA R, OVERGAARD J: Combination studies with combretastatin and radiation: effects in early and late responding normal tissues Radiother. Oncol. (2002) 64:S50.
33. DOWLATI A, ROBERTSON K, COONEY M et al.: A Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. (2002) 62:3408-3416.
34. STEVENSON JP, ROSEN M, SUN W et al.: Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol. (2003) 21:4428-4438.
35. RUSTIN GJ, GALBRAITH SM, ANDERSON H et al.: Phase I clinical trial of weeldy combrecastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol. (2003) 21:2815-2822.
36. GALBRAITH SM, MAXWELL RJ, LODGE MA et al.: Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol. (2003) 21:2831-2842.
37. ANDERSON HL, YAPP JT, MILLER MP, ROBBINS A, JONES T, PRICE PM: Assessment of pharmacodynamic vascular response in a Phase I trial of combretastatin A4 phosphate. J. Clin. Oncol. (2003) 21:2823-2830.
38. YOUNG SL, CHAPLIN DJ: Combretasmtin A4 phosphate: background and current clinical status. Expert Opin. Investig. Drugs (2004) 13:1171-1182.
39. WEST CM, PRICE P: Combretastatin A4 phosphate. Anticancer Drugs (2004) 15:179-187.
40. COONEY MM, SAVVIES P AGARWALA S et al.: Phase II study of Combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid cancer (ATC). J. Clin. Oncol. (2006) 24:(Abstract 5580).
41. RUSTIN GJ, NATHAN PD, BOXALL J et al.: Dose escalation study combining Combretastatin A4 phosphate (CA4P) with carboplatin and/or paclitaxel in patients with advanced cancer. Proceeding; of AACR-NCI-EORTC Conjirence. Molecular Targets and Cancer Therapeutics, Prague, Czech Republic (2006) (Abstract A12).
42. BILENKER JH, FLAHERTY KT, ROSEN M et al.: Phase I trial of combretastatin A4 phosphate with carboplatin. Clin. Cancer Res. (2005) 11:1527-1533.
43. ACKERLEY WL, SCHABEL M, MORREL G et al.: Randomized Phase II trial of combretasratin A4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies. J. Clin. Oncol. (2007) 25:(Abstract 14060).
44. NG QS, CARNELL D, MILNER J, SAUNDER MI, HOSKIN PJ: Phase I trial of combretastatin A4 phosphate (CA4P) in combination with radiotherapy (RT). Initial clinical results. J. Clin. Oncol. (2005) 23:(Abstract 3117).
45. NG QS, GOH V CARNELL D et al.: Tumor antivascular effects of radiotherapy combined with combretastatin A4 phosphate in human non small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. (2007) 67: 1375-1380.
46. RICARD AD, COONEY M, SARANTOPOULOS J et al.: A Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MN-029, a novel vascular disrupting agent (VDA) in patients with advanced solid tumors. J. Clin. Oncol. (2006) 24:(Abstract 3096).
47. GADGEEL SM, LORUSSO PM, WOZNIAK AJ, WHEELER C: A dose-escalation study of the novel vascular-targeting agent ZD6126, in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21:(Abstract 438).
48. THORPE PE, CHAPLIN DJ, BLAKEY DC: The first international conference on vascular targeting; Meeting overview. Cancer Res. (2003) 63:1144-1147.
49. EVELHOCH JL, LORUSSO PM, HE Z et al.: Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-cargetitig agent ZD6126. Clin. Cancer Res. (2004) 10:3650-3657.
50. BEEREPOOT LV, RADEMA SA, WITTEYEEN EO et al.: Phase I clinical evaluation of weekly administration of the novel vascular targeting agent, ZD6126, in patients with solid tumors. J. Clin. Oncol. (2006) 24:1485-1488.
51. TOLCHER AW, FERERO P, CELIO LA et al.: Phase I, pharmacokinctic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28-days. Proc. Am. Soc. Clin. Oncol. (2003) 22:(Abstract 834).
52. SESSA C, LORUSSO PM, TOLCHER AW et al.: A pharmacokinetic and DCE-MRI-dynamic Phase I study of the antivascular combretastatin analogue AVE8062A administered every 3 weeks. Proc. Am. Assoc. Cancer Res. (200 5) 46:(Abstract 5827).
53. JOUANNOT E, CARREZ C, LASSAUN et al.: Demonstration in animal and human of AVE8062-induced tumor blood shutdown using dynamic contrast crihanced-ultrasonograpliy. Proceedings of Annual Meeting ofthe American Association for Cancer Research, Los Angeles, USA (2007):(Abstract LB-328).
54. LORUSSO P, PAPADOPOULOS K, TOLCHER A et al.: A Phase I accelerated titration dose escalation of the vascular disrupting agent NPI-2358 utilizing MRI. Proceedings of Annual Meeting of the American Association for Cancer Research, Los Angeles, CA, USA (2007):(Abstract 3987).
55. PATTERSON DM, ROSS P, KOETZ B et al.: Phase I evaluation of OXi4503, a vascular disrupting agent, in patients with advanced solid tumors. J. Clin. Oncol. (2007) 25:(Abstract 14146).
56. RUSTIN GJ, BRADLEY C, GALBRAITH S et al.: 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: Phase I clinical and pharmacokinetic study. Br. J. Cancer (2003) 88:1160-1167.
57. JAMESON MB, THOMPSON PL, BAGULEY BC et al.: Clinical aspects of a Phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br. J. Cancer (2003) 88:1844-1850.
58. GALBRAITH SM, RUSTIN GJ, LODGE MA et al.: Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J. Clin. Oncol. (2002) 20:3826-3840.
59. MCKEAGUE MJ, FONG P, JEFFREY M et al.: 5,6-Dimethyl xanthenone-4-acetic acid in the treatment of refractory tumors: a Phase I safety study of a vascular disrupting agent. Clin. Cancer Res. (2006) 12:1776-1784.
60. MCKRAGE MJ: Phase I/II study of DMXAA combined with carboplatin and paclicaxel in non-small cell lung cancer (NSCLC). J. Clin. Oncol. (2006) 24:(Abstract 7102).
61. GABRA H: Phase II study of DMXAA combined with carboplatin and paclitaxel in recurrent ovarian cancer. J. Clin. Oncol. (2006) 24:(Abstract 5032).
62. ROSENTHAL M, PILI R: Randomized Phase II study of docetaxel with or without DMXAA (AS1404) in hormone - refractory metastatic prostate cancer (HRMPC). American Society of Clinical Oncology Prostate Cancer Symposium, Orlando, USA (2007):(Abstraci 219).
63. VON PAWEL J, RECK M, MCKEAGE M: Update on survival in a Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non small cell lung cancer (NSCLC). Eur. J. Cancer Supp. (2007) 4:16.
64. BLASCHUK OW, ROWLANDS TM: Cadherins as modulators of angiogenesis and the structural integrity of blood vessels. Cancer Metast. Rev. (2000) 19:1-5.
65. LEPEKHIN E, JIANG S, MICHAUD A et al.: Early and long term effects of exherin on tumor vasculature. Proc. Am. Soc. Clin. Oncol. (2003) 22:(Abstract 883).
66. JONKER Dj, STEWART DJ, GOEL R et al.: A Phase I study of the novel molecularly targeted vascular targeting agent, exherin (ADH-I) shows activity in some patients with refractory solid tumors stratified according to N-cadherin exprcssion. J. Clin. Oncol. (2005) 23:(Abstract 3038).
67. STEWART DJ, JONKER DJ, GOEL R et al.: Final clinical and pharmacokinetic (PK) results from a phasel study of the novel N-cadherin (N-cad) antagonist, Exherin (ADH-1), in patients with refractory solid rumors stratified according to N-cad expression. J. Clin. Oncol. (2006) 24:(Abstract 3016).
68. SESSA C, PEROTTI A, MAUR M et al.: An enriched Phase I, pharmacokinetic and pharmacodynamic study of the N-cadherin (NCAD) cyclic competitive binder exherin (ADH-I) in patients with solid tumors. J. Clin. Oncol. (2006) 24:(Abstract 3042).
69. PEROTTI A, MANCUSO A, MAUR M et al.: Final results of the Phase I/ II study of the N-cadherin(N-cad) antagonist ADH-1 in patients with solid tumors. Procedings of 5th International Symposium Targeted on Cancer Therapy, Amsterdam, The Netherlands (2007): (Abstract 0204).
70. RUSTIN GJ, NATHAN PD, BOXHALL J, SAUNDERS L, GANESAN TS, SHREEVES GE: A Phase Ib trial of combretastatin A-4 phosphate (CA4P) in combination with carboplatin or paclitaxel chemotherapy in patients with advanced cancer, J. Clin. Oncol. (2005) 23:(Abstract 3013).
71. PLATTS SH, FALCONE JC, HOLTON WT, HILL MA, MENINGER GA: Alteration of micrombule polymerization modulates arteriolar vasomotor tone. Am. J. Physiol. (1999) 277:H100-H106.
72. HONESS DJ, HYLANDS F, CHAPLIN DJ, TOZER GM: Comparison of strategies to overcome the hypertensive effect of combretastatin-A-4-phosphate in a rat model. Br. J. Cancer (2002) 86:S118.
73. KESTELL P, ZHAO L, JAMESON MB, STRATFORD W, FOLKES LK, BAGULEY BC: Measurements of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clin. Chim. Acta (2001) 314:159-166.
74. SHAKED Y, CIARROCHI A, FRANCO M et al.: Therapy induced acute recruitment of circulating endothelial cell progenitor cells to tumors. Science (2006) 313:1785-1787.
75. RICE, LEPLER S, PAMPO C, SIEMANN DW: Vascular targeting agents alter circulating endothelial progenitor cells in mice with or without tumors. Proceedings of Annual Meeting of the American Association for Cancer Research, Los Angeles, USA (2007):(Abstract 4629).
76. SORIA J-C, FARACE F, LASSAU N: Vascular disrupting agents. Procedings of 5th International Symposium Targeted on Cancer Therapy, Amsterdam, The Netherlands (2007):(Abstract 0305).